Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism
July 13, 2016 at 09:24 AM EDT
The first Phase 3 trials for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)'s Syk inhibitor are expected to be announced in August as many ...
